The Therapeutic Landscape in Chronic Cough.

IF 4.6 2区医学 Q1 RESPIRATORY SYSTEM

Lung Pub Date : 2024-02-01 Epub Date: 2023-12-21 DOI:10.1007/s00408-023-00666-y

Jaclyn A Smith

引用次数: 0

Abstract

In recent years, there has been a substantial increase in the development of antitussive therapies and the first new therapy, gefapixant has been licenced in Europe. This review describes current unlicenced treatments for chronic cough and details treatments currently in development for refractory chronic cough and cough in idiopathic pulmonary fibrosis, as well as compounds previously explored.

查看原文本刊更多论文

慢性咳嗽的治疗前景

近年来，止咳疗法的开发大幅增加，第一种新疗法吉非那君（gefapixant）已在欧洲获得许可。本综述介绍了目前未获批准的慢性咳嗽治疗方法，并详细介绍了目前正在开发的用于治疗难治性慢性咳嗽和特发性肺纤维化咳嗽的治疗方法，以及以前探索过的化合物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Lung 医学-呼吸系统

CiteScore

9.10

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Lung publishes original articles, reviews and editorials on all aspects of the healthy and diseased lungs, of the airways, and of breathing. Epidemiological, clinical, pathophysiological, biochemical, and pharmacological studies fall within the scope of the journal. Case reports, short communications and technical notes can be accepted if they are of particular interest.